Latest Clinical Studies on Microcurrent Neurofeedback: What the Science Says
2026 brings many new and exciting clinical studies for the field of Microcurrent Neurofeedback.
Over the past few years, clinical studies have shown great benefits to depression, anxiety, and post-traumatic stress disorder.
2026 is currently shaping up to be an incredible year for expanding both the reach and understanding of the benefits of MCN.
Studies currently underway in 2026 include studies on traumatic brain injuries, light sensitivity in post-concussive symptoms of headache,
insomnia and attention disorder, and reduced symptoms of cravings for substance use disorders.
Recent Completed and Published MCN Research:
MCN Helps with Severe Mental Health Disruptions
A breakthrough exploratory pilot study published in the Journal of the American Association of Nurse Practitioners
specifically evaluated the effectiveness of IASIS Microcurrent Neurofeedback (I-MCN) on adults battling severe mental health disruptions. [1,2]
The Study Basics:
20 adults experiencing elevated clinical levels of depression, anxiety, and/or post-traumatic stress disorder (PTSD).
Participants received brief, passive I-MCN sessions twice a week over a 10-week span (totaling 20 sessions).
Data was strictly tracked and collected at baseline, week 5 (10 sessions), and week 10 (20 sessions). [1,2]
The Outcomes: Rapid Symptom Reduction in Mental Health Disruptions
through Microcurrent Neurofeedback.
The trial yielded highly statistically significant data regarding how fast the brain responds to low-intensity,
pulse-based transcranial electrical stimulation (LIP-tES): [1]
By the 10th session (5 weeks of treatment), participants already showed significant clinical improvements
across depression scales, anxiety levels, and overall PTSD risk. [1]By the 20th session, these improvements were not only sustained but further solidified, accompanied
by a measurable boost in daily Quality of Life (QOL) metrics. [1]The treatment was noted as safe, non-invasive, and highly feasible for standard clinical environments,
offering a functional alternative for individuals dealing with treatment-resistant conditions. [1]Overall Outcome: This peer-reviewed pilot data confirms that microcurrent neurofeedback effectively
"interrupts" frozen, hyper-vigilant brain patterns far faster than older, active operant-conditioning neurofeedback methods. [1,2]
2026 Research on Microcurrent Neurofeedback:
Current and Ongoing MCN Studies
Neurofeedback for Concussion-Related Light Sensitivity
The goal of this study is to reduce light sensitivity in Veterans with mild traumatic brain injury (mTBI).
Researchers aim to determine if MCN approach is effective and acceptable for those with light sensitivity.
Participants must have a history of mTBI, ongoing light sensitivity, and a recent eye exam showing no major vision problems.
As an unphased trial, this study offers Veterans the chance to explore a novel treatment option for light sensitivity.
This is the link to apply for this current study.
Microcurrent Neurofeedback for Substance Use Disorders
A newly completed clinical trial out of the University of Alabama (Tuscaloosa) evaluated the feasibility
and efficacy of adding Microcurrent Neurofeedback (MCN) to standard residential treatment for adults
struggling with Substance Use Disorder (SUD).
The trial specifically utilized the IASIS MCN device, which is an FDA-cleared Class 2 biofeedback technology.
IASIS is the device that Erin uses in her office in Los Gatos for Microcurrent Neurrofeedback.
Breakdown of the MCN Study
61 adult patients (aged 18–65) actively enrolled in a residential substance use treatment program who had already completed
a 4-week stabilization period.A randomized, open-label pilot trial where patients were divided into two parallel groups:
Standard Care Alone: Received routine residential care (medications, individual/group cognitive behavioral therapy, and 12-step support).
Standard Care + MCN: Received standard care plus 12 sessions of MCN over a 12-week period (each session lasted 30–45 minutes).
Researchers gathered standardized questionnaire data at baseline, 6 weeks, and 12 weeks. A small subset of patients also underwent
EEG tracking and MRI brain scans to explore structural neurological changes.
Objectives and Questions of MCN study
Because this was a pilot and feasibility trial, the researchers focused heavily on operational delivery alongside patient symptoms.
The study set out to answer three core questions:
Craving Reduction: Does adding MCN to standard therapy reduce substance cravings more than standard treatment alone?
Co-Occurring Symptoms: Does MCN help further lower the severe symptoms of depression, anxiety, and PTSD t
hat frequently trigger substance relapse?Clinical Feasibility: Is it practical and achievable to deliver microcurrent stimulation sessions within the tight,
busy schedule of an active residential rehab facility?
This study has concluded, however the results have not been published yet.
Sign up on their website to receive email notifications when the results are published.